Previous Article | Next Article 
Journal of Virology, May 2001, p. 4407-4412, Vol. 75, No. 9
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.9.4407-4412.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
PR Domain of Rous Sarcoma Virus Gag Causes an
Assembly/Budding Defect in Insect Cells
Marc C.
Johnson,*
Heather M.
Scobie, and
Volker
M.
Vogt*
Department of Molecular Biology and Genetics,
Cornell University, Ithaca, New York 14853
Received 25 August 2000/Accepted 20 December 2000
 |
ABSTRACT |
While baculovirus expression of Gag proteins from numerous
retroviruses has led reliably to production of virus-like particles (VLPs), we observed that expression of Rous sarcoma virus Gag failed to
produce VLPs. Transmission and scanning electron microscopy analysis
revealed that the Gag protein reached the plasma membrane but was
unable to correctly form particles. Addition of a myristylation signal
had no effect on the budding defect, but deletion of the PR domain of
Gag restored normal budding. The resulting VLPs were morphologically
distinct from human immunodeficiency virus type 1 VLPs expressed in parallel.
 |
TEXT |
The baculovirus expression
system has been widely used in the study of retrovirus assembly,
with examples including human immunodeficiency virus (HIV) types 1 and
2; simian, bovine, and feline immunodeficiency viruses; Mason-Pfizer
monkey virus, and human T-cell lymphotropic virus type 2 as well as the
retrotransposon TED and the human endogenous retrovirus HERV-K
(2, 4, 9, 11, 12, 16, 22, 26, 27). In each case,
expression of the gag gene led to the production of regular
virus-like particles (VLPs). In contrast, we have found that the Rous
sarcoma virus (RSV) Gag protein is an exception; overexpression of the
gag gene yielded high levels of protein but negligible
production of extracellular VLPs.
Two aspects of RSV Gag distinguish it from the other retroviral Gag
proteins. First, RSV Gag is not myristylated at its N terminus
(13). Myristylation is known to be required for budding of
most of the well-studied retroviruses (17, 18). Similarly, when a single amino acid change to abolish myristylation was introduced into baculovirus-produced SIV or HIV-1 Gag, intracellular VLPs were
still produced, but they were unable to exit the cells (2, 4). Hence, it seemed possible that the budding defect of RSV is
due to lack of myristylation. Second, unlike most other retroviruses, RSV encodes the viral protease (PR) as part of Gag. Retroviral PR
domains cause difficulties in overexpression systems at two different
levels. Proteins encoding an active PR domain inevitably are poorly
produced in the baculovirus system (7), presumably because
the PR enzyme is cytotoxic. For some purposes this difficulty can be
overcome by using an active-site mutant of PR. In addition, retroviral
PR domains are extremely insoluble (6, 10, 21). Expression
of an HIV-1 Gag protein with an inactivated PR domain at its C terminus
(creating a molecule equivalent to RSV Gag) resulted in a reduction of
extracellular VLP production by 5- to 10-fold compared with wild-type
Gag, and the particles produced had a lower density and were irregular
in shape (19). These data suggest that the PR domain might
lead to unnatural aggregation or precipitation of RSV Gag in the
baculovirus overexpression system, in effect preventing proper budding.
To investigate the possible causes of the RSV-specific budding defect
in insect cells, we created three recombinant baculoviruses (Fig.
1). The first expresses the Gag mutant
Myr2, which carries an artificially introduced N-terminal myristylation
signal. This mutant is infectious when introduced into an RSV proviral
construct (14). The second recombinant baculovirus,
PR,
expresses an RSV Gag mutant in which the first amino acid of the PR
domain is replaced by a stop codon, effectively deleting the PR domain. The third baculovirus, Myr0, expresses RSV Gag with a wild-type membrane-binding domain. The Myr2, Myr0, and
PR constructs were originally subcloned into the baculovirus transfer vector pFastBac1 (Life Technologies) from plasmids pSV.Myr2 (14),
p
SV.Myr0 (29), and pET3xcGag
PR (1a),
respectively, using standard cloning techniques (Fig. 1). Constructs
then were shuttled into baculovirus according to the Bac-to-Bac
baculovirus expression system protocol (Life Technologies). In initial
experiments, Gag constructs which contained active PR were used, but it
was found that the protein yield from these constructs was
extraordinarily low, presumably due to PR-associated toxicity (data not
shown). To avoid this PR-associated toxicity, the PR domains of Myr0
and Myr2 were exchanged with the inactivated PR domain from plasmid
pgag.neo.D37N (25). The recombinant baculovirus Gag12myr
(20) expressing wild-type HIV-1 Gag was used as a positive
control for assembly and budding.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 1.
Baculovirus clones used in this study. Boxed amino acid
sequence represents wild-type sequence (top) and altered Myr2 sequence
(bottom). The X through the PR domain denotes an inactive protease.
Numbers represent amino acid positions of domain borders.
|
|
To determine the optimal time of protein expression, single flasks of
Sf9 cells growing in suspension culture were infected at a multiplicity
of infection of 0.1, and samples were harvested each day for 5 days.
With each virus, the total Gag protein both inside the cells and in the
medium increased progressively until day 3. After that, the level of
extracellular Gag stabilized, while intracellular Gag decreased
dramatically, presumably due to protein degradation (data not shown).
For this reason, all budding assays were performed by infecting at the
same low multiplicity of infection and collecting virus 2 to 3 days
postinfection. Gag protein from each baculovirus clone was initially
characterized by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) analysis. Infected Sf9 cells were
steady-state labeled with [35S] methionine (2 µCi/ml)
in methionine-reduced medium (0.1 mM methionine) from 1 day
postinfection until collection at 3 days postinfection. VLPs were
collected from culture medium by centrifugation through a 10% sucrose
cushion at 100,000 × g for 90 min. Proteins were
separated by SDS-15% PAGE and detected by PhosphorImager analysis of
fixed, dried gels (Fig. 2). In order to
highlight the differences among the viruses, 10 times more of the VLP
pellet than of the cell lysate (as a percentage of the total) was
loaded. The results from several experiments showed that less than 5% of Myr0 and Myr2 protein was released into the medium in particulate form, whereas 15 to 25% of
PR protein and 30 to 50% of HIV-1 protein was released. In the particular experiment shown, the percentage of total viral protein detected in the medium was 40, 20, 2, and 2% for HIV,
PR, Myr2, and Myr0, respectively.

View larger version (80K):
[in this window]
[in a new window]
|
FIG. 2.
SDS-PAGE analysis of VLP production. (A) 35S
detection. (B) Western blots. The amount of cells or medium loaded on
the gel is shown above each well.
|
|
Compared with the
PR and HIV-1 Gag proteins, the Myr0 and Myr2
proteins in cell lysates differed markedly in solubility. For example,
in a pulse-chase experiment, baculovirus-infected cells were labeled
for 20 min with [35S]methionine, and then lysates were
prepared in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% deoxycholate,
0.1% SDS, 50 mM Tris[pH 7.0]). While over 80% of the newly
synthesized
PR and HIV-1 Gag was soluble in these conditions, over
60% of the Myr2 protein was insoluble, as evidenced by ability to be
collected by centrifugation for 5 min at 14,000 × g
(data not shown). Similar results were obtained after different chase
times. Myr0 Gag was not analyzed by pulse-chase but was identical to
Myr2 in other solubility experiments. This information led us to
hypothesize that Myr0 and Myr2 proteins do not bud properly because
they are shuttled into inclusion bodies and consequently do not reach
the plasma membrane. To test this hypothesis, infected cells as well as
VLP pellets from each virus were thin sectioned and viewed by
transmission electron microscopy (TEM). For TEM analysis, infected
cells and VLPs were harvested 3 days postinfection, fixed with 2.5%
glutaraldehyde, postfixed with 1% osmium tetroxide, dehydrated through
a graded series of ethanol and ethanol-Spurr (23) washes,
and embedded in pure Spurr. Embedded samples were thin sectioned and
viewed on a Phillips 301 transmission electron microscope.
No occluded masses of proteins or clusters of assembled particles were
detected by TEM within cells infected with Myr0 or Myr2 (not shown).
However, thin sections at the plasma membrane showed abnormal
structures for Myr0 and Myr2. While
PR-infected and HIV-1-infected
cells displayed regular retrovirus-like particles budding at the plasma
membrane (Fig. 3A and E, respectively), Myr0-infected and Myr2-infected cells displayed dense aggregates at the
plasma membrane that vaguely resembled incompletely formed particles
(shown for Myr2 in Fig. 3C). Immunofluorescence analysis by confocal
microscopy confirmed that each of the RSV proteins resided
predominantly at the plasma membrane (not shown). Images of
thin-sectioned viral pellets collected from the medium reflect what was
seen at the plasma membrane (Fig. 3B, D, and F). While all pellets
contained regular, rod-shaped baculovirus particles, only HIV-1 and
PR pellets showed evidence of regular VLPs resembling immature
retroviruses. The Myr0 and Myr2 pellets contained what appear to be
irregular or broken particles. In conclusion, although each of the RSV
Gag proteins was able to reach the plasma membrane,
PR was the only
RSV protein able to properly assemble into viral particles. We take
these observations as evidence that membrane targeting is not
compromised in Myr0 or Myr2.

View larger version (129K):
[in this window]
[in a new window]
|
FIG. 3.
Thin-section TEM. (A, C, and E) Plasma membrane of Sf9
cells infected with PR, Myr2, and HIV-1, respectively. (B, D, and F)
VLP pellets from growth medium of cells infected with PR, Myr2, and
HIV-1, respectively. (G) Mixed pellet containing both PR and HIV-1
VLPs. (H) Infectious RSV particles. The RSV is infectious virus of the
RCAS strain (15). Solid triangles indicate RSV VLPs, open
triangles show HIV-1 VLPs, and arrows show baculovirus particles. Bars,
100 nm.
|
|
VLPs produced by the
PR construct exhibit a morphology distinct from
other VLPs. All baculovirus-produced retroviral VLPs that have been
reported are similar to HIV-1 VLPs, exhibiting a dense inner ring very
near the surface of the particle (2, 4, 11, 12, 16, 22,
26). The inner ring observed in
PR particles, however, was
distinctly closer to the center. To highlight the difference between
the two types of VLPs, a mixed pellet of HIV-1 and
PR particles was
sectioned and viewed by TEM (Fig. 3G). In addition to the difference in
morphology, the
PR particles were noticeably smaller than HIV-1
VLPs. The size distributions of VLPs and of the dark inner rings of RSV
PR, HIV-1, and authentic infectious RSV (Fig. 3H) collected from
infected turkey cells are shown in Fig.
4.
PR VLPs were relatively homogenous in size but were approximately 10 to 15 nm smaller in diameter than
mature infectious RSV (RCAS strain), and approximately 40 nm smaller
than HIV-1 VLPs. The diameter of the dark inner ring of
PR particles
was approximately half the diameter of the ring from HIV-1 particles.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 4.
Size distribution of particles and inner rings. BV RSV
and BV HIV-1 are baculovirus produced PR and HIV-1 VLPs,
respectively. Numbers in parentheses are the standard deviations of the
particle sizes. n, number of particles counted.
|
|
To provide a better overview of the altered budding structures,
infected cells were also examined by scanning electron microscopy (SEM)
(Fig. 5). Cells and VLPs were harvested
at 3 days postinfection, fixed with 2.5% glutaraldehyde, postfixed
with 1% osmium tetroxide, dehydrated through a graded series of
ethanol washes, critical point dried, mounted onto aluminum stubs, and
viewed on a Hitachi 4500 SEM. The surface of cells infected with
baculoviruses expressing
PR or HIV-1 (Fig. 5B and D, respectively)
was covered with clusters of perfectly round VLPs. In contrast, the
surface of cells expressing Myr0 or Myr2 showed irregular, lumpy, or
imperfectly spherical budding structures (Fig. 5C).

View larger version (197K):
[in this window]
[in a new window]
|
FIG. 5.
SEM analysis of baculovirus-infected and uninfected Sf9
cells. (A) Uninfected Sf9 cell. (B) PR-infected cell. (C)
Myr0-infected cell. (D) HIV-1-infected cell. Bars, 1 µm.
|
|
An important conclusion from this work is that the RSV Gag protein is
defective for budding when highly expressed in insect cells. A similar
finding has recently been reported for the Gag protein of human T-cell
leukemia virus (1). The RSV defect is caused by the presence of the PR
domain and not by a failure of the protein to reach the plasma
membrane. Since RSV Gag buds properly from both mammalian and avian
cells (8, 24), the budding defect is either due to the
cell type or peculiar to the baculovirus expression system. We
speculate that a chaperone activity in vertebrate cells promotes proper
folding and assembly of PR-containing proteins and that this activity
is not present in invertebrate cells or is quantitatively insufficient
in the baculovirus system. Other differences between insect and
vertebrate cells also might contribute to or be responsible for the
budding defect, for example, growth temperature and membrane composition.
A further conclusion is that baculovirus-produced
PR particles
viewed by thin-section TEM are 10 to 15 nm smaller in average diameter
than infectious RSV particles collected from avian cells. Although this
difference is distinct, the size distributions of the two viruses do
overlap. Several explanations might account for this difference. First,
the membrane of infectious RSV is studded with viral envelope proteins,
possibly making the membrane and therefore the particle diameter appear
thicker than the membrane of the baculovirus-produced particles.
Second, because the
PR protein is 124 amino acids smaller than
wild-type Gag, it could pack differently, yielding a particle with a
smaller radius of curvature. Third, the maturation triggered by
proteolytic processing of wild-type Gag conceivably could lead to
expansion of the diameter of the virion. This explanation seems the
least likely, as protease-deficient and wild-type murine leukemia virus
particles measured by cryo-EM have identical diameters
(30).
Finally,
PR VLPs are distinct from HIV-1 VLPs in both size and
morphology. The larger size of the HIV-1 VLPs is striking, with an
observed 40-nm-larger particle diameter, implying about a twofold
difference in volume. The size difference does not correlate with
genome lengths, which are similar for RSV and HIV-1. The measurements
by thin-section TEM are approximately 20% smaller than has been
reported for RSV and HIV-1 particles analyzed more accurately by
cryo-EM (3, 5; R. L. Kingston, personal
communication). This degree of shrinkage commonly occurs during the
fixation and dehydration procedures. The
PR particles are
morphologically distinct from HIV-1 particles in that the dark inner
rings of
PR particles are both smaller, approximately half the
diameter, and more central than the rings in HIV-1 particles. The
difference in the organization of the Gag domains of the
PR and
HIV-1 Gag proteins in part may account for these observed differences.
The N terminus of RSV CA begins at amino acid residue 239, while that of HIV-1 CA begins at residue 132. Overall, the differences between the
baculovirus-expressed RSV
PR and HIV-1 Gag particles imply a
different Gag stoichiometry. The estimated number of Gag molecules in
wild-type RSV is about 1,500 (28), and in particles
assembled in vitro it is about 1,200 (31). Similar
measurements have not been reported for HIV-1.
 |
ACKNOWLEDGMENTS |
We thank John Wills for the RSV constructs pSV,Myr2.T14K and
p
SV.Myr0 and Pierre Boulanger for the baculovirus Gag12myr. We
credit Thomas Wilk for originally observing that regular VLPs could not
be found in the medium of baculovirus-infected insect cells expressing
a PR-defective RSV Gag protein.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular Biology and Genetics, Cornell University, Ithaca, NY 14853. Phone: (607) 255-2443. Fax: (607) 255-2428. E-mail: vmvl{at}cornell.edu; mcj7{at}cornell.edu.
 |
REFERENCES |
| 1.
|
Bouamr, F.,
L. Garnier,
F. Rayne,
A. Verna,
N. Rebeyrotte,
M. Cerutti, and R. Z. Mamoun.
2000.
Differential budding efficiencies of human T-cell leukemia virus type I (HTLV-I) Gag and Gag-Pro polyproteins from insect and mammalian cells.
Virology
278:597-609[CrossRef][Medline].
|
| 1a.
|
Campbell, S., and V. M. Vogt.
1997.
In vitro assembly of virus-like particles with Rous sarcoma virus Gag deletion mutants: identification of the p10 domain as a morphological determinant in the formation of spherical particles.
J. Virol.
71:4425-4435[Abstract].
|
| 2.
|
Delchambre, M.,
D. Gheysen,
D. Thines,
C. Thiriart,
E. Jacobs,
E. Verdin,
M. Horth,
A. Burny, and F. Bex.
1989.
The GAG precursor of simian immunodeficiency virus assembles into virus-like particles.
EMBO J.
8:2653-2660[Medline].
|
| 3.
|
Fuller, S. D.,
T. Wilk,
B. E. Gowen,
H. G. Krausslich, and V. M. Vogt.
1997.
Cryo-electron microscopy reveals ordered domains in the immature HIV-1 particle.
Curr. Biol.
7:729-738[CrossRef][Medline].
|
| 4.
|
Gheysen, D.,
E. Jacobs,
F. de Foresta,
C. Thiriart,
M. Francotte,
D. Thines, and M. De Wilde.
1989.
Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells.
Cell
59:103-112[CrossRef][Medline].
|
| 5.
|
Gross, I.,
H. Hohenberg,
T. Wilk,
K. Wiegers,
M. Grattinger,
B. Muller,
S. Fuller, and H. G. Krausslich.
2000.
A conformational switch controlling HIV-1 morphogenesis.
EMBO J.
19:103-113[CrossRef][Medline].
|
| 6.
|
Hruskova-Heidingsfeldova, O.,
M. Andreansky,
M. Fabry,
I. Blaha,
P. Strop, and E. Hunter.
1995.
Cloning, bacterial expression, and characterization of the Mason-Pfizer monkey virus proteinase.
J. Biol. Chem.
270:15053-15058[Abstract/Free Full Text].
|
| 7.
|
Hu, Y. W., and C. Y. Kang.
1991.
Enzyme activities in four different forms of human immunodeficiency virus 1 pol gene products.
Proc. Natl. Acad. Sci. USA
88:4596-4600[Abstract/Free Full Text].
|
| 8.
|
Krishna, N. K.,
S. Campbell,
V. M. Vogt, and J. W. Wills.
1998.
Genetic determinants of Rous sarcoma virus particle size.
J. Virol.
72:564-577[Abstract/Free Full Text].
|
| 9.
|
Lerch, R. A., and P. D. Friesen.
1992.
The baculovirus-integrated retrotransposon TED encodes Gag and Pol proteins that assemble into viruslike particles with reverse transcriptase.
J. Virol.
66:1590-1601[Abstract/Free Full Text].
|
| 10.
|
Leuthardt, A., and J. L. Roesel.
1993.
Cloning, expression and purification of a recombinant poly-histidine-linked HIV-1 protease.
FEBS Lett.
326:275-280[CrossRef][Medline].
|
| 11.
|
Luo, L.,
Y. Li, and C. Y. Kang.
1990.
Expression of gag precursor protein and secretion of virus-like gag particles of HIV-2 from recombinant baculovirus-infected insect cells.
Virology
179:874-880[CrossRef][Medline].
|
| 12.
|
Morikawa, S.,
T. F. Booth, and D. H. Bishop.
1991.
Analyses of the requirements for the synthesis of virus-like particles by feline immunodeficiency virus gag using baculovirus vectors.
Virology
183:288-297[CrossRef][Medline].
|
| 13.
|
Palmiter, R. D.,
J. Gagnon,
V. M. Vogt,
S. Ripley, and R. N. Eisenman.
1978.
The NH2-terminal sequence of the avian oncovirus gag precursor polyprotein (Pr76gag).
Virology
91:423-433[CrossRef][Medline].
|
| 14.
|
Parent, L. J.,
C. B. Wilson,
M. D. Resh, and J. W. Wills.
1996.
Evidence for a second function of the MA sequence in the Rous sarcoma virus Gag protein.
J. Virol.
70:1016-1026[Abstract].
|
| 15.
|
Petropoulos, C. J., and S. H. Hughes.
1991.
Replication-competent retrovirus vectors for the transfer and expression of gene cassettes in avian cells.
J. Virol.
65:3728-3737[Abstract/Free Full Text].
|
| 16.
|
Rasmussen, L.,
J. K. Battles,
W. H. Ennis,
K. Nagashima, and M. A. Gonda.
1990.
Characterization of virus-like particles produced by a recombinant baculovirus containing the gag gene of the bovine immunodeficiency-like virus.
Virology
178:435-451[CrossRef][Medline].
|
| 17.
|
Rein, A.,
M. R. McClure,
N. R. Rice,
R. B. Luftig, and A. M. Schultz.
1986.
Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus.
Proc. Natl. Acad. Sci. USA
83:7246-7250[Abstract/Free Full Text].
|
| 18.
|
Rhee, S. S., and E. Hunter.
1987.
Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids.
J. Virol.
61:1045-1053[Abstract/Free Full Text].
|
| 19.
|
Royer, M.,
M. Bardy,
B. Gay,
J. Tournier, and P. Boulanger.
1992.
Proteolytic activity in vivo and encapsidation of recombinant human immunodeficiency virus type 1 proteinase expressed in baculovirus-infected cells.
J. Gen. Virol.
78:131-142[Abstract].
|
| 20.
|
Royer, M.,
S. S. Hong,
B. Gay,
M. Cerutti, and P. Boulanger.
1992.
Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells.
J. Virol.
66:3230-3235[Abstract/Free Full Text].
|
| 21.
|
Sellos-Moura, M., and V. M. Vogt.
1996.
Proteolytic activity of purified avian sarcoma and leukemia virus NC-PR protein expressed in Escherichia coli.
Virology
221:335-345[CrossRef][Medline].
|
| 22.
|
Sommerfelt, M. A.,
C. R. Roberts, and E. Hunter.
1993.
Expression of simian type D retroviral (Mason-Pfizer monkey virus) capsids in insect cells using recombinant baculovirus.
Virology
192:298-306[CrossRef][Medline].
|
| 23.
|
Spurr, A. R.
1969.
A low-viscosity epoxy resin embedding medium for electron microscopy.
J. Ultrastruct. Res.
26:31-43[CrossRef][Medline].
|
| 24.
|
Stewart, L.,
G. Schatz, and V. M. Vogt.
1990.
Properties of avian retrovirus particles defective in viral protease.
J. Virol.
64:5076-5092[Abstract/Free Full Text].
|
| 25.
|
Stewart, L., and V. M. Vogt.
1991.
trans-Acting viral protease is necessary and sufficient for activation of avian leukosis virus reverse transcriptase.
J. Virol.
65:6218-6231[Abstract/Free Full Text].
|
| 26.
|
Takahashi, R. H.,
K. Nagashima,
T. Kurata, and H. Takahashi.
1999.
Analysis of human lymphotropic T-cell virus type II-like particle production by recombinant baculovirus-infected insect cells.
Virology
256:371-380[CrossRef][Medline].
|
| 27.
|
Tonjes, R. R.,
K. Boller,
C. Limbach,
R. Lugert, and R. Kurth.
1997.
Characterization of human endogenous retrovirus type K virus-like particles generated from recombinant baculoviruses.
Virology
233:280-291[CrossRef][Medline].
|
| 28.
|
Vogt, V. M., and M. N. Simon.
1999.
Mass determination of Rous sarcoma virus virions by scanning transmission electron microscopy.
J. Virol.
73:7050-7055[Abstract/Free Full Text].
|
| 29.
|
Wills, J. W.,
R. C. Craven, and J. A. Achacoso.
1989.
Creation and expression of myristylated forms of Rous sarcoma virus Gag protein in mammalian cells.
J. Virol.
63:4331-4343[Abstract/Free Full Text].
|
| 30.
|
Yeager, M.,
E. M. Wilson-Kubalek,
S. G. Weiner,
P. O. Brown, and A. Rein.
1998.
Supramolecular organization of immature and mature murine leukemia virus revealed by electron cryo-microscopy: implications for retroviral assembly mechanisms.
Proc. Natl. Acad. Sci. USA
95:7299-7304[Abstract/Free Full Text].
|
| 31.
|
Yu, F.,
S. M. Joshi,
Y. M. Ma,
R. L. Kingston,
M. N. Simon, and V. M. Vogt.
2001.
Characterization of Rous sarcoma virus Gag particles assembled in vitro.
J. Virol.
75:2753-2764[Abstract/Free Full Text].
|
Journal of Virology, May 2001, p. 4407-4412, Vol. 75, No. 9
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.9.4407-4412.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Keller, P. W., Johnson, M. C., Vogt, V. M.
(2008). Mutations in the Spacer Peptide and Adjoining Sequences in Rous Sarcoma Virus Gag Lead to Tubular Budding. J. Virol.
82: 6788-6797
[Abstract]
[Full Text]
-
Ako-Adjei, D., Johnson, M. C., Vogt, V. M.
(2005). The Retroviral Capsid Domain Dictates Virion Size, Morphology, and Coassembly of Gag into Virus-Like Particles. J. Virol.
79: 13463-13472
[Abstract]
[Full Text]
-
Johnson, M. C., Scobie, H. M., Ma, Y. M., Vogt, V. M.
(2002). Nucleic Acid-Independent Retrovirus Assembly Can Be Driven by Dimerization. J. Virol.
76: 11177-11185
[Abstract]
[Full Text]